Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002635249 | SCV002963464 | uncertain significance | Congenital muscular dystrophy due to integrin alpha-7 deficiency | 2022-07-26 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 715 of the ITGA7 protein (p.Val715Ile). This variant is present in population databases (rs369291330, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with ITGA7-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV002635249 | SCV003815717 | uncertain significance | Congenital muscular dystrophy due to integrin alpha-7 deficiency | 2019-10-14 | criteria provided, single submitter | clinical testing | |
Gene |
RCV003314741 | SCV004014194 | uncertain significance | not provided | 2023-07-07 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004927834 | SCV005599322 | uncertain significance | not specified | 2024-09-26 | criteria provided, single submitter | clinical testing | The c.2143G>A (p.V715I) alteration is located in exon 15 (coding exon 15) of the ITGA7 gene. This alteration results from a G to A substitution at nucleotide position 2143, causing the valine (V) at amino acid position 715 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |